MetabolismInflammationBiomarkers
Cancer-Associated Cachexia
The lab investigates the metabolic and inflammatory drivers of cachexia to identify biomarkers, mechanisms, and intervention points that improve patient outcomes.
Cancer Biology · Metabolism · Immunology · Translation
Huang Lab
CAR T
Gang Huang Lab is an interdisciplinary research group at UT Health San Antonio and Mays Cancer Center spanning hematology, solid tumors, metabolism, immunology, trauma research, and product development.
UT Health San Antonio and Mays Cancer Center
San Antonio, Texas
0
Peer-reviewed publications
0
Lab members
0
Research programs
0
Spinout companies
Overview
Welcome to the Huang Lab
At The Huang Lab, we are dedicated to advancing the understanding and treatment of human disease through rigorous, multidisciplinary research. Under the leadership of Dr. Gang Huang, our team seeks to bridge fundamental discoveries with real-world applications, with a particular emphasis on hematology, metabolism, cancer biology, medical product development, CAR T-cell therapy, trauma research, and military health.
We focus on the complexities of both blood-related cancers and solid tumors while exploring how metabolic pathways and immune responses influence disease progression. By integrating expertise across these domains, we strive to develop innovative interventions that improve patient care and outcomes worldwide.
Research
Programs in motion
MDS / MPNLeukemiaStem cells
Blood Disorders and Hematologic Malignancies
The lab studies MDS, MPN, acute leukemia, and blood disorders by connecting stem cell regulation with mitochondrial metabolism and epigenetic control.
Liver cancerCAR TTumor microenvironment
Solid Tumor Immunotherapies
The lab builds next-generation immunotherapies for solid tumors, with emphasis on liver cancer, CAR T-cell engineering, and the tumor immune microenvironment.
Blood oxygen carriersUS Army ISRDoD collaborations
Trauma and Military Health
The lab develops synthetic blood oxygen carriers and trauma-relevant therapeutics, working with the U.S. Army Institute of Surgical Research and Department of Defense partners.
How we work
From bench to business to bedside
-
Discovery
Mechanisms of cancer, metabolism, immune dysfunction, and trauma at the bench.
-
Validation
Models and translational assays that pressure-test each target and technology.
-
Spinout
Companies formed around validated technologies — like Powerhouse Therapeutics and Abioremedi.
-
Development
IND-enabling studies, manufacturing, capital, and partnerships that carry products to market.
-
Bedside
Therapies reaching patients — in clinics, trauma care, and the field.
Spin-outs
Companies spun out
A Huang Lab spinout developing solid tumor immunotherapies, led by its IT-ACTS platform.
IT-ACTSPH102Solid tumor immunotherapy
Visit company
A Huang Lab spinout developing a synthetic blood oxygen carrier for trauma, transfusion medicine, and battlefield care.
Synthetic blood oxygen carrierTrauma & military health
Visit companyJoin the lab
Join our team
The lab welcomes postdoctoral scholars, graduate students, undergraduates, post-baccalaureate researchers, and staff who want to work on cancer biology, metabolism, immunology, genetics, and translational therapeutics.
Prospective trainees should fill out the application form and contact current lab members about positions.
News
Recent updates
Jun 15, 2026
Huang Lab Publishes Review on CAR T Cell Therapy in Solid Tumors in Hematological Oncology
The Huang Lab published a review in Hematological Oncology on the biological barriers limiting CAR T cell therapy in solid tumors and the engineering strategies to overcome them.
Read articleJun 10, 2026
Vincent Pham Named a 2026 Future Texas Business Legend by the Texas Business Hall of Fame
Vincent Pham was named a 2026 Future Texas Business Legend by the Texas Business Hall of Fame, receiving the Carlos & Malú Alvarez Award.
Read articleMay 12, 2026
Alejandra Lorenzen to Present Huang Lab Research at the AIM 2026 Health R&D Summit
Alejandra Lorenzen will present Huang Lab work on a synthetic blood oxygen carrier (OcVe) at the AIM 2026 Health R&D Summit, where Huang Lab members and Abioremedi will meet partners.
Read article